A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| MK-142 dimethanesulfonate | MK-142 is a bioactive agent with antiarrhythmic properties with its content in the skeletal muscles indicates a high affinity of the examined substance to the heart muscle. Uses: Antiarrhytmic. Synonyms: MK142; MK-142; MK 142; 3,3'-(ethane-1,2-diylbis(azanediyl))bis(1-(4-methoxyphenoxy)propan-2-ol). Grades: ≥95%. CAS No. 42794-63-8. Molecular formula: C22H32N2O6. Mole weight: 420.50. |  |
| MK-1775 | MK-1775, also known as AZD-1775, is a WEE1 inhibitor and a small-molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. MK-1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Unlike normal cells, most p53-deficient or mutated human cancers lack the G1 checkpoint as p53 is the key regulator of the G1 checkpoint and these cells rely on the G2 checkpoint for DNA repair to damaged cells. Annulment of the G2 checkpoint may therefore make p53-deficient tumor cells more vulnerable to antineoplastic agents and enhance their cytotoxic effect. Synonyms: MK-1775; MK1775; MK 1775; AZD1775; AZD-1775; AZD 1775; adavosertib. 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-prop-2-enylpyrazolo[3,4-d]pyrimidin-3-one. Grades: >98%. CAS No. 955365-80-7. Molecular formula: C27H32N8O2. Mole weight: 500.607. | |
| MK190 | MK190 is a synthetic bio-active chemical. Uses: A synthetic bio-active chemical. Synonyms: MK190; MK-190; MK 190; 2-(4-fluorophenyl)-1-methyl-5-nitro-1H-imidazole. Grades: ≥98%. CAS No. 4204-99-3. Molecular formula: C10H8FN3O2. Mole weight: 221.19. | |
| MK 1903 | MK 1903 is a hydroxycarboxylic acid receptor 2 (GPR109A) agonist. It may be used in the treatment of obesity and related weight disorders. Synonyms: MK 1903; MK1903; MK-1903; (4aR, 5aR)-4, 4a, 5, 5a-Tetrahydro-1H-cyclopropa[4, 5]cyclopenta[1, 2]pyrazole-3-carboxylic acid. Grades: ≥98% by HPLC. CAS No. 1268882-43-4. Molecular formula: C8H8N2O2. Mole weight: 164.16. | |
| MK 1903 | MK 1903. Group: Biochemicals. Grades: Purified. CAS No. 1268882-43-4. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| MK 1-907 | MK-1-907 is a centrally acting drug, but no detailed information has been published yet. Uses: Centrally acting drug. Synonyms: MK1907; MK-1-907; MK-1907; MK1-907; MK-1-907; 3- ( (3-methoxyphenyl)amino)-5, 5-dimethyl-2- ( (methyl (phenethyl)amino)methyl)cyclohex-2-en-1-one. Grades: 98%. CAS No. 78150-06-8. Molecular formula: C25H32N2O2. Mole weight: 392.54. | |
| MK-2048 | MK-2048 represents a prototype second generation integrase strand transfer inhibitor (INSTI), it was developed with the goal of retaining activity against viruses containing mutations assiciated with resistance of first-generation INSTIs, raltegravir. MK-2048 exhibits inhibitory activity towards HIV integrase and towards HIV replication. It is four times more effective in inhibiting HIV enzyme integrase than the first generation inhibitor, raltegravir. Group: Biochemicals. Alternative Names: (6S)-2-(3-Chloro-4-fluorobenzyl)-8-ethyl-10-hydroxy-N, 6-dimethyl-1, 9-dioxo-1, 2, 6, 7, 8, 9-hexahydropyrazino[1', 2':1, 5]pyrrolo[2, 3-d]pyridazine-4-carboxamide. Grades: Highly Purified. CAS No. 869901-69-9. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK-2048 | MK-2048 is a second generation integrase inhibitor (IC50=2.6 nM). It can inhibits the HIV enzyme integrase 4 times longer than raltegravir. Synonyms: MK2048; MK 2048; MK-2048. Grades: >98%. CAS No. 869901-69-9. Molecular formula: C22H24FN5O4. Mole weight: 441.46. | |
| MK212 | MK212 is a 5HT2C-receptor agonist. It exhibited anxiolytic activity in mice at low doses. It is a serotonin agonist. It could promote the secretion of serum prolactin and cortisol in humans. Uses: Mk212 exhibites anxiolytic activity and could promote the secretion of serum prolactin and cortisol in humans. Synonyms: MK212; MK 212; MK-212; 2-Chloro-6-(1-piperazinyl)pyrazine;MK-212;2-Chloro-6-(piperazin-1-yl)pyrazine. Grades: 98%. CAS No. 64022-27-1. Molecular formula: C8H11ClN4. Mole weight: 198.65. | |
| MK 212 hydrochloride | MK 212 hydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 61655-58-1. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK212 hydrochloride | MK212 hydrochloride is a selective 5-HT2C serotonin receptor agonist. It displays selectivity for 5-HT2C over 5-HT2A with IC50 values of 0.028 and 0.42 μM for human 5-HT2C and 5-HT2A receptors expressed in HEK293 cells respectively. Uses: Serotonin receptor agonists. Synonyms: MK212; MK 212; MK-212; MK-212 hydrochloride;1-(6-Chloro-2-pyrazinyl)piperazine monohydrochloride;2-Chloro-6-(1-piperazinyl)pyrazine monohydrochloride. Grades: 98%. CAS No. 61655-58-1. Molecular formula: C8H12Cl2N4. Mole weight: 235.11. | |
| MK-2206 | MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. It is also an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It binds to and inhibits the activity of Akt in a non-ATP competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. It has potential antineoplastic activity. It exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models. It induces G1-phase cell cycle arrest in hepatocellular carcinoma cells, inhibits cell proliferation in non-small cell lung cancer cells, and inhibits proliferation in medullary thyroid cancer cells. It also inhibits tumor growth in animal models of nasopharyngeal cancer. It was developed by Merck Sharp & Dohme and in clinic phase 2 trials. Uses: Mk-2206 has potential antineoplastic activity. Synonyms: MK2206; MK 2206; MK-2206; 8-(4-(1-Aminocyclobutyl)phenyl)-9-phenyl-8,9-dihydro-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one;8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one. Grades: 95%. CAS No. 1032349-93-1. Molecular formula: C25H21N5O. Mole weight: 407.47. | |
| MK-2206 | MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC 50 s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1032349-77-1. Pack Sizes: 5 mg; 10 mg. Product ID: HY-108232. |  |
| MK-2206 | MK-2206 Inhibitor. Uses: Scientific use. Product Category: T1952. CAS No. 1032350-13-2. |  |
| MK-2206 (8-(4-(1-Aminocyclobutyl)phenyl-9-phenyl[1, 2, 4]triazolo[3, 4-f][1, 6]naphthyridin-3(2H)-one Dihydrochloride) | A highly selective non-ATP competitive allosteric Akt inhibitor with IC??s of 8nM, 2nM and 65nM for Akt1, Akt2 and Akt3, respectively. MK-2206 potently inhibits phosphorylation of Thr308 and Ser473 in 3T3-L1 adipocytes with IC?? values of 0.11 and 0.18uM, respectively as well as downstream effects of insulin on GLUT4 translocation (IC?? = 0.47uM) and glucose transport (IC?? = 0.14uM). In addition, treatment with MK-2206 causes a robust, concentration-dependent activation of autophagy in human glioma cell lines LN229 and T98G. Group: Biochemicals. Grades: Highly Purified. CAS No. 1032350-13-2. Pack Sizes: 500ug, 1mg. US Biological Life Sciences. | Worldwide |
| MK-2206 dihydrochloride | MK-2206 dihydrochloride. Group: Biochemicals. Alternative Names: 8-[4- (1-Aminocyclobutyl) phenyl]-9-phenyl-1, 2, 4-triazolo[3, 4-f][1, 6]naphthyridin-3 (2H) -one hydrochloride. Grades: Highly Purified. CAS No. 1032350-13-2. Pack Sizes: 25mg, 50mg, 100mg, 250mg, 500mg. Molecular Formula: C25H23Cl2N5O. US Biological Life Sciences. | Worldwide |
| MK-2206 dihydrochloride | MK-2206 dihydrochloride (MK-2206 (2HCl)) is an orally active, BBB-penetrated allosteric AKT inhibitor with IC 50 s of 5 nM, 12 nM, and 65 nM for AKT1 , AKT2 , and AKT3 , respectively. MK-2206 dihydrochloride induces autophagy [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MK-2206 (2HCl). CAS No. 1032350-13-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10358. | |
| MK-2206 dihydrochloride | MK-2206 is a highly selective Akt inhibitor with IC50 of 8 nM, 12 nM and 65 nM for Akt1, Akt2 and Akt3, respectively. It is undergoing a phase II clinical trial for the treatment of ovarian, fallopian tube, or primary peritoneal cancer where there are mutations in P13K or AKT or low levels of PTEN. Synonyms: MK-2206. MK 2206. MK2206. Grades: >98%. CAS No. 1032350-13-2. Molecular formula: C25H23Cl2N5O. Mole weight: 480.4. | |
| MK-2206 hydrochloride | MK-2206 hydrochloride is the hydrochloride form of MK-2206, which is an allosteric inhibitor of Akt and an orally bioavailable allosteric inhibitor of the serine/threonine protein kinase Akt (protein kinase B). It has potential antineoplastic activity. It exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models. It inhibits tumor growth in animal models of nasopharyngeal cancer. Uses: Mk-2206 hydrochloride has potential antineoplastic activity. Synonyms: MK-2206 hydrochloride; MK 2206 hydrochloride; 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl-2H-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3-one hydrochloride;MK2206 hydrochloride. Grades: >98 %. CAS No. 1032349-77-1. Molecular formula: C25H22ClN5O. Mole weight: 443.93. | |
| MK-2295 | MK-2295 is a potent TRPV1 antagonist. TRPV1 antagonists has the potential as analgesic and anti-inflammatory agents. Synonyms: MK-2295; MK 2295; MK2295; 6-[(3R)-4-[6-(4-fluorophenyl)-2-[(2R)-2-methylpyrrolidin-1-yl]pyrimidin-4-yl]-3-methylpiperazin-1-yl]-5-methylpyridine-3-carboxylic acid; 6-{4-[6-(4-Fluoro-phenyl)-2-(2-methyl-pyrrolidin-1-yl)-pyrimidin-4-yl]-3-(R)-methyl-piperazin-1-yl}-5-methyl-nicotinic acid; 3-Pyridinecarboxylic acid, 6-[(3R)?-4-[6-(4-fluorophenyl)?-2-[(2R)?-2-methyl-1-pyrrolidinyl]?-4-pyrimidinyl]?-3-methyl-1-piperazinyl]?-5-methyl-; 878811-00-8 (free base); 1855897-95-8 (mesylate salt). Grades: >98%. CAS No. 878811-00-8. Molecular formula: C27H31FN6O2. Mole weight: 490.58. | |
| MK-2461 | MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met. MK-2461 inhibited in vitro phosphorylation of a peptide substrate recognized by wild-type or oncogenic c-Met kinases (N1100Y, Y1230C, Y1230H, Y1235D, and M1250T) with IC50 values of 0.4 to 2.5 nmol/L. In tumor cells, MK-2461 effectively suppressed constitutive or ligand-induced phosphorylation of the juxtamembrane domain and COOH-terminal docking site of c-Met, and its downstream signaling to the phosphoinositide 3-kinase-AKT and Ras-extracellular signal-regulated kinase pathways, without inhibiting autophosphorylation of the c-Met activation loop. In cell culture, MK-2461 inhibited hepatocyte growth factor/c-Met-dependent mitogenesis, migration, cell scatter, and tubulogenesis. In a murine xenograft model of c-Met-dependent gastric cancer, a well-tolerated oral regimen of MK-2461 administered at 100 mg/kg twice daily effectively suppressed c-Met signaling and tumor growth. Synonyms: MK 2461; MK2461; MK-2461. Grades: >98%. CAS No. 917879-39-1. Molecular formula: C24H25N5O5S. Mole weight: 495.554. | |
| MK-251 | MK-251 is a synthetic bio-active chemical. Uses: A synthetic bio-active chemical. Synonyms: MK 251; MK251; alpha,alpha-Dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl)benzylamine. Grades: ≥98%. CAS No. 40396-83-6. Molecular formula: C17H17F4N. Mole weight: 311.32. | |
| MK 287 | MK-287 is platelet activating factor (PAF) inhibitor originated by Merck & Co. It can potently inhibit [3H]C18-PAF binding to human platelet, PMN (polymorphonuclear leukocyte) and lung membranes. The inhibitory effects are competitive and stereospecific. Clinical trials for asthma was discontinued. Uses: Asthma. Synonyms: MK-287; MK 287; MK287; L-680573; L 680573; L680573;2-((3-methoxy-2-propoxy-5-((2S,5S)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran-2-yl)phenyl)sulfonyl)ethan-1-ol. Grades: 98%. CAS No. 135947-75-0. Molecular formula: C25H34O9S. Mole weight: 510.60. | |
| MK-2894 | MK-2894, a nonacylsulfonamide analogue, is a high affinity full antagonist against the EP4 receptor. It is found to have conceivable potency and selectivity for further study and might be safer than traditional Non-steroidal anti-inflammatory drugs and co. Uses: Mk-2894, a nonacylsulfonamide analogue, is a high affinity full antagonist against the ep4 receptor. Synonyms: MK-2894; MK 2894; MK2894; CHEMBL597997; 1006036-87-8; 4- [1- [ [2, 5-dimethyl-4- [ [4- (trifluoromethyl) phenyl] methyl] thiophene-3-carbonyl] amino] cyclopropyl] benzoicacid; C25H22F3NO3S; GTPL4041. Grades: 95%. CAS No. 1006036-87-8. Molecular formula: C25H22F3NO3S. Mole weight: 473.51. | |
| MK-2894 Na salt | The sodium salt form of MK-2894 that is found to have conceivable potency and selectivity for further study and might be safer than traditional Non-steroidal anti-inflammatory drugs and coxibs in the treatment of pain and inflammation. IC50: 2.5 nM (Ki=0. Uses: The sodium salt form of mk-2894 that is found to have conceivable potency and selectivity in the treatment of pain and inflammation. Synonyms: MK-2894 Na salt; MK 2894 Na salt; MK2894 Na salt; sodium; 4-[1-[[2, 5-dimethyl-4-[[4- (trifluoromethyl) phenyl]methyl]thiophene-3-carbonyl]amino]cyclopropyl]benzoate; MK-2894 (sodiumsalt) ; 1006036-88-9; MK-2894Nasalt; C25H21F3NO3S. Na. Grades: 95%. CAS No. 1006036-88-9. Molecular formula: C25H21F3NNaO3S. Mole weight: 495.49. | |
| MK-2 Dye | MK-2 Dye. Group: Organic solar cell (opv) materials. CAS No. 1037440-21-3. Product ID: (Z)-2-cyano-3-[5-[5-[5-[5-(9-ethylcarbazol-3-yl)-3-hexylthiophen-2-yl]-3-hexylthiophen-2-yl]-3-hexylthiophen-2-yl]-3-hexylthiophen-2-yl]prop-2-enoic acid. Molecular formula: 955.5g/mol. Mole weight: C58H70N2O2S4. CCCCCCC1=C (SC (=C1) C2=C (C=C (S2) C3=C (C=C (S3) C4=C (C=C (S4) C5=CC6=C (C=C5) N (C7=CC=CC=C76) CC) CCCCCC) CCCCCC) CCCCCC) C=C (C#N) C (=O) O. InChI=1S / C58H70N2O2S4 / c1-6-11-15-19-25-40-34-52 (63-50 (40) 38-45 (39-59) 58 (61) 62) 55-43 (27-21-17-13-8-3) 36-54 (65-55) 57-44 (28-22-18-14-9-4) 37-53 (66-57) 56-42 (26-20-16-12-7-2) 35-51 (64-56) 41-31-32-49-47 (33-41) 46-29-23-24-30-48 (46) 60 (49) 10-5 / h23-24, 29-38H, 6-22, 25-28H2, 1-5H3, (H, 61, 62) / b45-38-. FOELOZKDLHJOHT-JYRXYQGCSA-N. |  |
| MK2-IN-1 | MK2-IN-1, a selective MAPKA-PK2 inhibitor, could probably influence the formation of proinflammatory cytokines. IC50: 0.11 uM. Uses: Mk2-in-1 is a selective mapka-pk2 inhibitor that could probably influence the formation of proinflammatory cytokines. Synonyms: MK2 Inhibitor. Grades: 98%. CAS No. 1314118-92-7. Molecular formula: C27H25ClN4O2. Mole weight: 472.97. | |
| MK2-IN-1 hydrochloride | The hydrochloride salt form of MK2-IN-1 which is a selective MAPKA-PK2 inhibitor and could probably influence the formation of proinflammatory cytokines. IC50: 0.11 uM. Uses: The hydrochloride salt form of mk2-in-1 which is a selective mapka-pk2 inhibitor and could probably influence the formation of proinflammatory cytokines. Synonyms: MK25; MK-25; MK 25; MK2 Inhibitor IV; MK2 Inhibitor-IV; MK2 Inhibitor. Grades: 98%. CAS No. 1314118-94-9. Molecular formula: C27H26Cl2N4O2. Mole weight: 509.43. | |
| MK2 Inhibitor III | MK2 inhibitor III is a cell-permeable and ATP-competitive inhibitor of mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2). It was shown to block LPS-induced synthesis of TNF-α in human monocyte-like U937 cells with IC50 value of 4.4 μM. Synonyms: 2-(2-(Quinolin-3-yl)pyridin-4-yl)-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4(5H)-one hydrate. Grades: ≥95%. CAS No. 1186648-22-5. Molecular formula: C21H16N4O·H2O. Mole weight: 358.4. | |
| MK-2 Inhibitor IV, MK-25 (MAPKAP-K2 Inhibitor IV, MK-25, 5-(4-Chlorophenyl)-N-(4-(piperazin-1-yl)phenyl)-N-(pyridin-2-ylmethyl)furan-2-carboxamide, HCl) | A cell-permeable furanylcarboxamide compound that acts as a potent, reversible and non-ATP-competitive inhibitor of MK-2/MAPKAP-K2 activity (IC50=110nM; EC50=350nM for pHSP27 in IL-1b-stimulated SW1353 cells) with excellent selectivity over 150 kinases (% activity inhibition at 10uM against human CK2, Haspin, Arg and CK1y3=40, 40, 42 and >70, respectively). Shown to efficiently suppress the secretions of TNFa, IL6 (IC50=4.4 and 5.2uM in LPS-stimulated THP1 cell, respectively) and MMP-13 (IC50=5.7 and 2.2uM in IL1b-stimulated SW1353 and in primary osteoarthritis-derived chondrocytes, respectively). Exhibits desirable bioavailability and weakly inhibits a panel of cytochrome P450 isozymes (IC50>20uM for 3A4, 2D6 and 2C9). Group: Biochemicals. Grades: Highly Purified. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| MK-3207 | MK-3207 is an orally active, highly selective and species-specific CGRP receptor antagonist (for human CGRP receptor : IC 50 =0.12 nM; K i =0.024 nM). MK-3207 can be used for migraine studies [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 957118-49-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-10301. | |
| MK-3207 | MK-3207 is a orally active and potent calcitonin gene-related peptide (CGRP) receptor antagonist IC50 vaule of 0.12 nM and Ki value of 0.024 nM. It is highly selective versus human AM1, AM2, CTR, and AMY3. It displays lower affinity for human CGRP receptors from other species, including canine and rodent. It is a potent antagonist of the human and rhesus monkey CGRP receptors in vitro. It produced a concentration-dependent inhibition of dermal vasodilation in vivo. It is effective acute migraine treatments. It was developed by Merck & Co., Inc. and was terminated in clinic phase 2. Uses: Mk-3207 is effective acute migraine treatments. Synonyms: MK3207; MK 3207; MK-3207; 2-[(8R)-8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro[4.5]decan-9-yl]-N-[(2R)-2'-oxospiro[1,3-dihydroindene-2,3'-1H-pyrrolo[2,3-b]pyridine]-5-yl]acetamide;(8R)-8-(3,5-Difluorophenyl)-10-oxo-N-[(2R)-1,1',2',3-tetrahydro-2'-oxospirv [4.5]decane-9-acetamide;6,9-Diazaspiro[4.5]decane-9-acetaMide,8-(3,5-difluorophenyl)-10-oxo-N-[(2R)-1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl]-,(8R)-. Grades: >98 %. CAS No. 957118-49-9. Molecular formula: C31H29F2N5O3. Mole weight: 557.59. | |
| MK-3207 HCl | MK-3207 is a potent CGRP receptor antagonist with IC50 and Ki of 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3. Synonyms: MK-3207 HCl; MK 3207 HCl; MK3207 HCl. Grades: >98%. CAS No. 957116-20-0. Molecular formula: C31H29F2N5O3·HCl. Mole weight: 594.05. | |
| MK-3207 Hydrochloride | MK-3207 (Hydrochloride) is a potent and orally bioavailable CGRP receptor antagonist with IC 50 of 0.12 nM and K i of 0.024 nM, and is highly selective versus human AM1, AM2, CTR, and AMY3. Uses: Scientific research. Group: Signaling pathways. CAS No. 957116-20-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-10302. | |
| MK-3328 | This molecular has a favorable potency versus human β-amyloid plaque and has been radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. Studies led to the identification of MK-3328 as a candidate PET ligand for the clinical assessment of β-amyloid plaque load. In Aug 2009, Phase-I clinical trials in Alzheimer's disease in Belgium was on-going, but no recent reported has been published yet. Uses: Alzheimer's disease. Synonyms: MK3328; MK 3328; MK-3328; 5-fluoro-2-(1-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)oxazolo[5,4-b]pyridine. Grades: 98%. CAS No. 1201323-97-8. Molecular formula: C14H9FN4O. Mole weight: 268.25. | |
| MK-351 hydrochloride | MK-351 hydrochloride is an alpha-adrenergic agonist selective for α2-adrenergic receptors. It is a psychoactive drug used as a sympatholytic or antihypertensive. It plays a role in treating hypertension and gestational hypertension. It has a dual mechanism of action. It is a competitive inhibitor of the enzyme DOPA decarboxylase, which converts L-DOPA into dopamine. It is converted to α-methylnorepinephrine by dopamine beta-hydroxylase. Uses: Mk-351 hydrochloride is a psychoactive drug used as a sympatholytic or antihypertensive. it plays a role in treating hypertension and gestational hypertension. Synonyms: MK-351 hydrochloride; MK 351 hydrochloride; MK351 hydrochloride; Alpha-Methyldopa hydrochloride;L-(-)-A-Methyldopa hydrochloride;Alpha-Methyldopa HCl;(2S)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;3-Hydroxy-alpha-methyl-L-tyrosine hydrochloride;L-Tyrosine, 3-hydroxy-alpha-methyl-, hydrochloride;Methyldopa hydrochloride. Grades: >98 %. CAS No. 884-39-9. Molecular formula: C10H14ClNO4. Mole weight: 247.68. | |
| MK-3697 | MK3697 is a highly potent, orally bioavailable selective orexin 2 receptor antagonists (2-SORAs) that possess acceptable profiles for clinical development. MK-3697 is also the third insomnia product, currently being developed by Merck. MK-3697 has Ki = 0.95 nM. Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. In vivo tests results on MK-3697 demonstrated improved stability and TDI profiles as well as excellent sleep efficacy across species. Synonyms: MK-3697; MK3697; MK 3697. Grades: 0.99. CAS No. 1224846-01-8. Molecular formula: C23H21N5O3S. Mole weight: 447.513. | |
| MK-386 | MK-386 is a human type I 5α-reductase inhibitor with selectivity for type I 5α-reductase over type II 5α-reductase (IC50 = 0.9 and 154 nM, respectively). It reduces dihydrotestosterone (DHT) in serum and sebum in a dose-dependent manner, suggesting its utilization in acne treatment. Uses: 5-alpha reductase inhibitors. Synonyms: MK 386; MK386; (4aR,4bS,6aR,7R,9aS,9bS,10S,11aR)-7-[(1R)-1,5-Dimethylhexyl]hexadecahydro-1,4a,6a,10-tetramethyl-2H-indeno[5,4-f]quinolin-2-one. Grades: ≥98% by HPLC. CAS No. 158493-17-5. Molecular formula: C28H49NO. Mole weight: 415.69. | |
| MK-3903 | MK-3903 is a potent and selective AMPK activator with EC50 value of 8 nM. Synonyms: MK 3903; MK3903; 5-[[6-Chloro-5-(4-phenylphenyl)-1H-benzimidazol-2-yl]oxy]-2-methylbenzoic acid. CAS No. 1219737-12-8. Molecular formula: C27H19ClN2O3. Mole weight: 454.90. | |
| MK-3984 | MK-3984 is a androgen receptor modulators. It can be used for the prevention and treatment of muscle wasting associated with cancer. Uses: Muscle wasting associated with cancer. Synonyms: MK3984; MK 3984; MK-3984; (R)-3,3,3-trifluoro-N-(2-fluoro-5-(trifluoromethyl)benzyl)-2-hydroxy-2-phenylpropanamide. Grades: 98%. CAS No. 871325-55-2. Molecular formula: C17H12F7NO2. Mole weight: 395.27. | |
| MK 410 | MK 410 is an anti-inflammatory drug which can induce alterations in the immune system by the suppression of plasma neutral proteinase activity. Uses: Anti-inflammatory. Synonyms: MK-410; MK 410; MK410; 2-(5-methoxy-2-methyl-1-(4-(methylthio)benzyl)-1H-indol-3-yl)propanoic acid. Grades: ≥98%. CAS No. 40738-05-4. Molecular formula: C21H23NO3S. Mole weight: 369.47. | |
| MK-4101 | MK-4101 is a potent and selective SMO Inhibitor of the Hedgehog Pathway with anti-tumor activity. MK-4101 targets the Hh pathway in tumor cells, showing the maximum inhibitory effect on Gli1 MK-4101 also induced deregulation of cell cycle and block of DNA replication in tumors. Synonyms: 5-(3,3-Difluorocyclobutyl)-3-[4-[4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl]bicyclo[2.2.2]oct-1-yl]-1,2,4-oxadiazole; MK-4101; MK 4101; MK4101. Grades: >98%. CAS No. 935273-79-3. Molecular formula: C24H24F5N5O. Mole weight: 493.48. | |
| MK 436 | MK436 is an anti-protozoal drug has been found to be effective against Trypanosoma cruzi infections. Uses: A therapeutic agent and an anti-protozoal drug. Synonyms: MK-436; MK 436; MK436; 3-(1-methyl-5-nitro-1H-imidazol-2-yl)-3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazole. Grades: ≥98%. CAS No. 33450-08-7. Molecular formula: C11H14N4O3. Mole weight: 250.10. | |
| MK-467 | MK-467 is a peripheral Alpha2 -adrenoceptor antagonist originated by Merck & Co. It can dose-dependently attenuate the bradycardia associated with dexmedetomidine, and shorten the sedative effect without altering its quality. Clinical for Diabetes mellitus in USA was discontinued in 1994. Uses: Diabetes mellitus. Synonyms: MK-467; MK 467; MK467; UNII-66932R910R; N-(2-((2R,12bS)-2'-oxo-1,3,4,6,7,12b-hexahydrospiro[benzofuro[2,3-a]quinolizine-2,4'-imidazolidin]-3'-yl)ethyl)methanesulfonamide hydrochloride. Grades: 98%. CAS No. 130466-38-5. Molecular formula: C20H27ClN4O4S. Mole weight: 454.98. | |
| MK-4827 hydrochloride | Cas No. 1038915-64-8. | |
| MK-4827 (R-enantiomer) | MK-4827 (R-enantiomer) is the R form of MK-4827, which is a PARP inhibitor developed for the treatment of ovarian cancer. Synonyms: (R)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; Niraparib R-enantiomer; MK4827 R-enantiomer; MK 4827 R-enantiomer; MK-4827 R-enantiomer. Grades: > 98%. CAS No. 1038915-58-0. Molecular formula: C19H20N4O. Mole weight: 320.396. | |
| MK-4827 tosylate | MK-4827 tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM. It has a great activity in cancer cells with mutant BRCA-1 and BRCA-2, >330-fold selective against PARP3, V-PARP and Tank1. Synonyms: (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide 4-methylbenzenesulfonate; MK-4827; MK-4827; MK4827; MK4827-tosylate; Niraparib tosylate. Grades: >98%. CAS No. 1038915-73-9. Molecular formula: C26H28N4O4S. Mole weight: 492.59. | |
| MK 499 | MK 499, also know as L706000, has been found to be a potassium channel antagonist that has been once studied the activity in the treatment of arrhythmias. The Phase II trail of it has already been discontinued by Merck. Synonyms: L 706000; L706000; L706000; MK 499; MK499; MK499. L 706000; L-706000; L-706,000; N-[1'-(6-cyano-1,2,3,4-tetrahydronaphthalen-2-yl)-4-hydroxyspiro[3,4-dihydrochromene-2,4'-piperidine]-6-yl]methanesulfonamide. Grades: 98%. CAS No. 150481-98-4. Molecular formula: C25H29N3O4S. Mole weight: 467.58. | |
| MK-5046 | MK-5046, the first BRS-3 agonist with properties suitable for use in larger mammals, has strong selectivity when binding to BRS-3 receptor. It was developed by Merck as a new approach to the treatment of obesity and still under phase I trial.(mouse Ki = 1. Uses: Mk-5046, the first brs-3 agonist with properties suitable for use in larger mammals, has strong selectivity when binding to brs-3 receptor. Synonyms: MK5046; MK-5046; MK 5046. (2R)-1, 1, 1-trifluoro-2-(4-pyrazol-1-ylphenyl)-3-[5-[[1-(trifluoromethyl)cyclopropyl]methyl]-1H-imidazol-2-yl]propan-2-ol; MK5046peak2; SCHEMBL502524; UJINBEQCDMOAHM-GOSISDBHSA-N; KB-78904; (2R)-1, 1, 1-trifluoro-2-[4-(1H-pyrazol-1-yl)phenyl]-3-(4-{[1-(trifluorom. Grades: 95%. CAS No. 1022152-70-0. Molecular formula: C20H18F6N4O. Mole weight: 444.37. | |
| MK-5172 | Grazoprevir is a hepatitis C virus protease inhibitor developed for the treatment of hepatitis C. It suppresses NS3 and NS4A, which play a role in the virus splitting its polyprotein into the functional virus proteins. Grazoprevir is often used in combination with elbasvir or ribavirin. Uses: Antiviral agents. Synonyms: Cyclopropanecarboxamide, N-[[[ (1R, 2R) -2-[5- (3-hydroxy-6-methoxy-2-quinoxalinyl) pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl- (4R) -4-hydroxy-L-prolyl-1-amino-N- (cyclopropylsulfonyl) -2-ethenyl-, cyclic (1?2)-ether, (1R,2S)-; Grazoprevir; (1R, 2S) -N-[[[ (1R, 2R) -2-[5- (3-Hydroxy-6-methoxy-2-quinoxalinyl) pentyl]cyclopropyl]oxy]carbonyl]-3-methyl-L-valyl- (4R) -4-hydroxy-L-prolyl-1-amino-N- (cyclopropylsulfonyl) -2-ethenylcyclopropanecarboxamide Cyclic (1?2)-Ether. Grades: >98%. CAS No. 1350514-68-9. Molecular formula: C38H50N6O9S. Mole weight: 766.91. | |
| MK-5172 hydrate | In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose. Uses: Antiviral agents. Synonyms: (33R,35S,91R,92R,5S)-5-(tert-butyl)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-17-methoxy-4,7-dioxo-2,8-dioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopropanacyclotetradecaphane-35-carboxamide hydrate; MK-5172; MK 5172; MK5172; Grazoprevir; Grazoprevir hydrate; trade name: Zepatier?. Grades: >98%. CAS No. 1350462-55-3. Molecular formula: C38H52N6O10S. Mole weight: 784.92. | |
| MK-5172 intermediate | Cas No. 1206524-85-7. | |
| MK-5172 potassium salt | In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose. Synonyms: Grazoprevir potassium salt; MK5172 potassium salt; MK 5172 potassium salt. Grades: >98%. CAS No. 1206524-86-8. Molecular formula: C38H49KN6O9S. Mole weight: 804.99. | |
| MK-5172 sodium salt | In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a. In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose. Synonyms: Grazoprevir sodium salt; MK5172 sodium salt; MK 5172 sodium salt. Grades: >98%. CAS No. 1425038-27-2. Molecular formula: C38H49N6NaO9S. Mole weight: 788.89. | |
| MK-5198 | MK-5108 is a novel small molecule with potent inhibitory activity against Aurora-A kinase. Although most of the Aurora-kinase inhibitors target both Aurora-A and Aurora-B, MK-5108 specifically inhibited Aurora-A kinase in a panel of protein kinase assays. Inhibition of Aurora-A by MK-5108 in cultured cells induced cell cycle arrest at the G(2)-M phase in flow cytometry analysis. The effect was confirmed by the accumulation of cells with expression of phosphorylated Histone H3 and inhibition of Aurora-A autophosphorylation by immunostaining assays. MK-5108 also induced phosphorylated Histone H3 in skin and xenograft tumor tissues in a nude rat xenograft model. MK-5108 inhibited growth of human tumor cell lines in culture and in different xenograft models. Furthermore, the combination of MK-5108 and docetaxel showed enhanced antitumor activities compared with control and docetaxel alone-treated animals without exacerbating the adverse effects of docetaxel. MK-5108 is currently tested in clinical trials and offers a new therapeutic approach to combat human cancers as a single agent or in combination with existing taxane therapies. Synonyms: MK5108; MK-5108; MK 5108; VX689; VX 689; VX-689. Grades: >98%. CAS No. 1010085-13-8. Molecular formula: C22H21ClFN3O3S. Mole weight: 461.94. | |
| MK 571 | MK 571. Group: Biochemicals. Grades: Purified. CAS No. 115104-28-4. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| MK 571 | MK-571 is a CysLT1 receptor antagonist. It can be used for the treatment of respiratory diseases. Uses: Leukotriene antagonists. Synonyms: MK 571; MK571; MK-571; 3-[[[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]propanoic acid. Grades: ≥98% by HPLC. CAS No. 115104-28-4. Molecular formula: C26H27ClN2O3S2. Mole weight: 515.09. | |
| MK-571 | A receptor antagonist for the treatment of respiratory diseases. Cysteinyl leukotriene receptor antagonist MK-571 alters bronchoalveolar lavage fluid proteome in asthma. Group: Biochemicals. Alternative Names: 3- [ [ [3- [ (1E) -2- (7-Chloro-2-quinolinyl) ethenyl] phenyl] [ [3- (dimethylamino) -3-oxopropyl] thio] methyl] thio] propanoic Acid. Grades: Highly Purified. CAS No. 115104-28-4. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| MK-571 | MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D 4 (LTD 4 ) receptor antagonist, with K i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: L-660711. CAS No. 115104-28-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19989. | |
| MK-571 Methyl Ester | Precursor to MK-571. Group: Biochemicals. Alternative Names: 3- [ [ [3- [ (1E) -2- (7-Chloro-2-quinolinyl) ethenyl] phenyl] [ [3- (dimethylamino) -3-oxopropyl] thio] methyl] thio] propanoic Acid Methyl Ester. Grades: Highly Purified. CAS No. 120443-15-4. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| MK-571 sodium | MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D 4 (LTD 4 ) receptor antagonist, with K i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: L-660711 sodium. CAS No. 115103-85-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-19989A. | |
| MK-571 sodium salt | Selective leukotriene LTD4 receptor antagonist. Potent MRP1 inhibitor. Antinociceptive. Group: Biochemicals. Grades: Highly Purified. CAS No. 115104-28-4. Pack Sizes: 5mg, 25mg. Molecular Formula: C26H26ClN2O3S2?Na. US Biological Life Sciences. | Worldwide |
| MK-571 sodium salt | The sodium salt hydrate of MK-571 which is an effective antagonist of CysLT1 receptor and an inhibitor of MRP1. Uses: Bronchodilator agents. Synonyms: sodium (E) -3- ( ( (3- (2- (7-chloroquinolin-2-yl) vinyl) phenyl) ( (3- (dimethylamino) -3-oxopropyl) thio) methyl) thio) propanoate; MK-571; MK 571; MK571; MK-571 sodium salt; L-660,711; L660,711; L 660,711; L-660711; L660711; L 660711. Grades: 95%. CAS No. 115103-85-0. Molecular formula: C26H26ClN2NaO3S2. Mole weight: 537.07. | |
| MK591 | Quiflapon is a synthetic compound which specifically inhibits the activity of 5-Lox and is currently under development for the treatment of asthma. Also, Quiflapon, a leukotriene biosynthesis inhibitor, induces apoptosis in prostate cancer cells. Synonyms: Quiflapon sodium; MK-591; MK 591. Grades: >98%. CAS No. 147030-01-1. Molecular formula: C34H34ClN2NaO3S. Mole weight: 609.15. | |
| MK-6240 | MK-6240 is a tau positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs) , exhibiting high specificity and selectivity for binding to NFTs [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1841078-87-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-101186. | |
| MK6-83 | MK6-83. Group: Biochemicals. Grades: Purified. CAS No. 1062271-24-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| MK6-83 | MK6-83 is a transient receptor potential channel ML3 activator with EC50 value of 110 nM. It can restore endolysosomal trafficking and zinc homeostasis in lysosomes of mucolipidosis type IV mutant fibroblasts. Synonyms: MK6-83; MK6 83; MK683; 5-Methyl-N-[2-(1-piperidinyl)phenyl]-2-thiophenesulfonamide. Grades: ≥98% by HPLC. CAS No. 1062271-24-2. Molecular formula: C16H20N2O2S2. Mole weight: 336.47. | |
| MK-6892 | MK-6892 is a highly potential GPR109A agonist. Synonyms: MK6892; MK 6892; MK-6892. Grades: >98%. CAS No. 917910-45-3. Molecular formula: C19H22N4O5. Mole weight: 386.4. | |
| MK-711 | MK-711 is used as a potential bioactive agent. Uses: Mk-711 is used as a potential bioactive agent. Synonyms: MK 711; MK711; 10,11-Dihydro-5-(1-methyl-4-piperidinylidene)-5H-dibenzo(a,d)cycloheptene-3-carboxylic acid; 5-(1-methylpiperidin-4-ylidene)-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxylic acid. Grades: 98%. CAS No. 63141-67-3. Molecular formula: C22H23NO2. Mole weight: 333.43. | |
| MK-7145 | This active molecular is a selective renal outer medullary potassium channel (RMOK) inhibitor originated by Merck Sharp & Dohme for the treatment of hypertension and heart failure. RMOK is an ATP-dependent potassium channel that transports potassium out of cells. MK-7145 is selective against other cardiac ion channels such as Cav1.2 and Nav1.5 with IC50 value > 30 μM. MK-7145 is the first small molecule ROMK inhibitor to enter clinical development. But in Feb 2015, Merck terminated a phase I trial in Hypertension in Australia and New Zealand. Uses: Hypertension and heart failure. Synonyms: MK-7145; MK 7145; MK7145; 5,5'-((1R,1'R)-piperazine-1,4-diylbis(1-hydroxyethane-2,1-diyl))bis(4-methylisobenzofuran-1(3H)-one);1255204-85-3 (2HCl). Grades: 98%. CAS No. 1255204-84-2. Molecular formula: C26H30N2O6. Mole weight: 466.53. | |
Our database is helping our users find suppliers everyday.
